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Abstract
Background: Serum antibody-based target identification has been used to identify tumor-associated antigens (TAAs) for
development of anti-cancer vaccines. A similar approach can be helpful to identify biologically relevant and clinically
meaningful targets in M.tuberculosis (MTB) infection for diagnosis or TB vaccine development in clinically well defined
populations.
Method: We constructed a high-content peptide microarray with 61 M.tuberculosis proteins as linear 15 aa peptide
stretches with 12 aa overlaps resulting in 7446 individual peptide epitopes. Antibody profiling was carried with serum from
34 individuals with active pulmonary TB and 35 healthy individuals in order to obtain an unbiased view of the MTB epitope
pattern recognition pattern. Quality data extraction was performed, data sets were analyzed for significant differences and
patterns predictive of TB+/2.
Findings: Three distinct patterns of IgG reactivity were identified: 89/7446 peptides were differentially recognized (in 34/34 TB+
patients and in 35/35 healthy individuals) and are highly predictive of the division into TB+ and TB2, other targets were
exclusively recognized in all patients with TB (e.g. sigmaF) but not in any of the healthy individuals, and a third peptide set was
recognized exclusively in healthy individuals (35/35) but no in TB+ patients. The segregation between TB+ and TB2 does not
clusterintospecificrecognitionofdistinctMTBproteins,butintospecificpeptideepitope‘hotspots’atdifferentlocationswithin
the same protein. Antigen recognition pattern profiles in serum from TB+ patients from Armenia vs. patients recruited in
Sweden showed that IgG-defined MTB epitopes are very similar in individuals with different genetic background.
Conclusions: A uniform target MTB IgG-epitope recognition pattern exists in pulmonary tuberculosis. Unbiased, high-
content peptide microarray chip-based testing of clinically well-defined populations allows to visualize biologically relevant
targets useful for development of novel TB diagnostics and vaccines.
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Introduction
Serum antibody-based target identification has been extensively
used to identify tumor-associated antigens (TAAs) for development
of anti-cancer vaccines and early diagnostic markers. cDNA tumor
expression libraries (SEREX, serological analysis of recombinant
cDNAexpression libraries) were instrumental inidentifying humoral
targets which were further tested for T-cell recognition in patients
with cancer [1]. B-cell antigens, and humoral and cellular targets
appeared to be closely linked in malignant disease: the majority of
TAAs have been identified using SEREX and proved to be
indicative of CD4+ and CD8+ T-cell responses [2,3,4]. A similar
approach can be helpful to identify biologically relevant and
clinically meaningful targets in M.tuberculosis infection for diagnosis
or TB vaccine development [5]. Comprehensive testing of immune
recognition in arrayed MTB antigens in a clinically well defined
population will help to reveal the profile of a successful protective
immuneresponse,mostlikely associated with CD4+ and CD8+ anti-
MTB responses [6,7,8,9,10] in individuals capable of containing
MTB infection. More recent studies have emphasized the usefulness
of antibody-based diagnostics in TB and although these have been
extensively tested in low-income countries, they did not deliver
sufficient accuracy and sensitivity since humoral immune responses
may depend on the individual and test sensitivity can vary
[11,12,13]. In most cases, these tests gauge antibody responses using
single recombinant TB antigens. The remedy to limited MTB target
testing would be the implementation of protein arrays, as recently
reported for autoantigens recognized by sera from patients suffering
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antigens is time-consuming and challenged by the need for correct
folding of the target antigen. An alternative approach represents the
construction of a high-content peptide microarray which displays a
comprehensive set of MTB antigens in the form of linear peptide
stretches without ‘pre-meditated’ target-selection. This approach
enables a detailed epitope profiling of the humoral immune response
and defines ‘hotspots’ of antibody recognition in clinically well
defined patient cohorts. Since T-cells are instrumental in mediating
anti-MTB responses, we examined IgG responses, whose presence
implies T-cell recognition.
Results
Serum profile using MTB peptide microarray analysis:
differential target recognition
Sera from 34 individuals with sputum, acid-fast positive,
pulmonary TB as well as 35 sera from healthy participants were
tested for recognition of 61 MTB proteins (listed with details and
segregated according to the MTB life cycle in the Supplementary
Table S1 online) in the form of single peptide epitopes. Each peptide
was 15aa and showed a 12aa overlap resulting in 7776 epitope spots
arranged in 24 blocks on the microarray slide. After incubation with
serum, antibody binding to individual peptides was identified
(Figure 1), and a cluster analysis of the two groups (TB+ and TB2
individuals) was carried out (Figure 2). Quality data was extracted as
described in materials and methods, and for each group we
normalized the responses of all peptides that were recognized in at
leastoneofthesamples.Threeindividualpatternsemerged:Peptides
recognized i) exclusively in TB+ individuals ii) exclusively in TB2
individuals and iii) peptides which are differentially recognized in the
two groups. We identified 1089 peptides that were exclusively
recognized in the TB+ group (Figure 3, left panel), 1001 in the TB2
group (Figure 3, right panel) and 89 common peptides that were
predictive of the groups by PAM analysis (see cluster image in
Figure 4) with an classification error of approximately zero. The ‘top
12’ most strongly predictive peptides are shown in Figure 3 (centre
panel), and the whole list is provided in Supplementary Table S2
online. These 89 peptides all appeared among the 172 peptides
identified by SAM analysis as having significantly higher response in
TB+ individuals, and also among the 301 with significantly lower
response (Supplementary Table S3 online).
Figure 1. Overview of peptide microarry chip analysis. The analysis platform (left) consists of two identical sub-arrays, each with 7776 spots
arranged in 24 blocks, each block has 324 spots, and these are arranged in columns and rows of 18. The 7776 peptide spots represent 7446 unique
peptides, 153 negative control spots, 96 Cy3 controls for GAL file orientation and 24 positive controls spots (4 repetitions each of IgG, IgA, IgM, IgE).
Plasma is tested for IgG binding to peptides and the slide is scanned with the GenPix 4000B microarray scanner (Axon Instruments with the features
described in the method section. A magnification (right) shows the Cy3 controls in order to orient the Gal file (mask) which allows the identification of
the aa sequence of each peptide printed in a designated location. Positive controls serve to detect the function of the secondary reagent, empty
spots are devoid of peptides, serum antibody-peptide antigen complexes are visualized using the appropriate secondary reagent. The plot shows a
representative positive result with the target epitope sequence identified.
doi:10.1371/journal.pone.0003840.g001
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TB2 individuals
A compilation of the ‘top 24’ peptides recognized in serum from
TB+ individuals but not in any sample from TB2 individuals are
segregated by proteins and compiled in the supplementary Table
S4 online. Of note, the segregation between TB+ and TB2 does
not cluster into specific recognition of certain MTB proteins, but
rather into specific peptide epitopes at different locations within
the same protein. For instance, the highly immunogenic Ag85B
mycolylstransferase protein Rv1888c is recognized in different
groups: the peptide epitope QSSFYSDWYSPACGK is exclusively
recognized in 34/34 of the TB+ individuals (and not in any of the
35 healthy TB2 individuals), while YNGWDINTPAFEWYY and
SPACGKAGCQTYKWE are exclusively recognized in 35/35 of
the TB2 group (Supplementary Tables S2, S3 and S4 online) and
WGPSSDPAWERNTDPT is strongly recognized in healthy
individuals but only weakly in individuals with acid-fast+ TB
(Figure 3, middle panel). Among the strongly recognized linear
peptide epitopes are peptides from protein antigens which have
been described in the past, e.g. Ag85B, or isocytrate dehydroge-
nase [15]. We identified additional target peptides from proteins
involved in cellular metabolism (glycosyl transferase), lipid-
degradation (acyl-CoA Synthase) or lipid formation (e.g. cyclo-
propane-fatty-acyl-phospholipid synthetase). The latter enzyme is
also present in MOTT (mycobacteria other than tuberculosis) and
could therefore be recognized in sera from healthy individuals,
exposed to MOTT.
Uniform Ig-recognition pattern in pulmonary TB
The formation of IgG is dependent on T-cell help, which is
determined by MHC class II-restricted presentation of antigenic
peptides. It may very well be that differences in the T-cell
‘immunome’, and the IgG B-cell recognition patterns the TB+ and
TB2 subjects presented in the current study is due to their
different genetic background and different exposure to environ-
mental bacterial species. We therefore obtained an additional 6
serum samples from Swedish individuals who presented with
pulmonary (acid-fast stain positive) TB in Stockholm, and
compared these with the 35 serum samples from the TB2
individuals and the 34 samples from the Armenian patients. The
average responses of peptides that were detectable in all patients in
either the two TB+ groups are presented in Figure 5A, where it
can be seen that (i) for peptides that are detected in both groups,
the magnitude of the responses are strongly correlated, (ii) this
correlation remains high when we limit to peptides that are never
recognized in the 35 healthy controls (iii) there is a group of
Figure 2. Cluster analysis of the normalized IgG responses from TB+ and TB2 individuals Spots flagged as ‘‘bad’’ and false positive
responses were excluded.
doi:10.1371/journal.pone.0003840.g002
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not from Armenia, and vice versa, and (iv) approximately half of
these exclusive peptides in each group are not recognized in any of
the 35 healthy controls. The sets of peptides defined by IgG
reactivity in patients (from Armenia and from Sweden), but not in
healthy controls have considerable overlap: from among the 100
top peptides exclusively recognized by IgG in TB+ individuals
from Armenia, but not in 35/35 TB-negative individuals, we
found 60 that were also recognized in the additional six TB+
patients from Sweden (Supplementary Table S5 online). The
responses in each patient group were highly coherent: most of the
peptides that had a response for any patient in a group had a
response for all patients in the group: this was true for 5864/5999
peptides for the 34 TB+ patients from Armenia and for 4733/
4748 peptides for the 6 patients recruited in Sweden.
The IgA immune responses in the sera from the 6 additional
patients showed a different profile than the IgG ‘immunome’: a
specific set of peptides were exclusively recognized by IgA and not
by IgG and vice versa, but for peptides recognized by both, the
responses were strongly correlated (r=0.75) (Figure 5B and
Supplementary Table S6 online).
Discussion
We studied the serum IgG recognition pattern inpatients with TB
and used as a paradigm a ‘high content chip’ peptide microarray
with 61 MTB proteins as linear peptide stretches. This excludes the
identification of conformation-dependent epitopes and non-protein
targets,e.g.carbohydrates,glycolipidsandfattyacidswhichmayalso
serve as biologically relevant targets for humoral and cellular
immune responses [16]. A recent survey examining TB-related
epitope data revealed that 65 percent of the known TB epitopes
derive from the top 30 most studied protein antigens, and that 357
humoral responses have been identified [17]. Until now, the most
frequent target proteins for T- and B-cell responses are associated
with either the cell wall (i.e. Ag85b, PE/PPE) or MTB pathogenicity
[17]. Indeed, Ag85B and PPE-protein family members were
Figure 3. IgG recognition of MTB epitopes segregates TB+ (marked in red) and TB2 (marked in green) individuals. The left panel
shows the peptides that gave a detectable response for 34/34 individuals with TB but were never recognized in any sample from 35 TB2 individuals.
Conversely, the right panel shows the responses of peptide epitopes that were recognized by 35/35 TB2 individuals but not recognized by any of the
34 TB+ individuals. A predictive analysis using PAM found 89 peptides differentially recognized by TB+ and TB2 individuals with a classification error
of approximately zero. The center panel plots the ‘top 12’ most strongly predictive of these: the header of each plot shows the peptide sequence, and
the corresponding protein with the accession number and the location of the peptide (given in brackets) within the protein is listed under each plot.
A compilation of the ‘top 24’ responses (boxed) of the peptides recognized exclusively by TB+ or TB2 individuals (left and right panel) segregated by
proteins are compiled in Supplementary Table S4 online. Segregation between TB+ and TB2 does not cluster into specific recognition of certain MTB
proteins, but rather into specific peptide epitopes at different locations within the same protein.
doi:10.1371/journal.pone.0003840.g003
Figure 4. Prediction of TB+ using pattern analysis. Differential
IgG responses to 89 peptides (listed in Supplementary Table S2 online)
identified by PAM analysis segregate TB+ from TB2 individuals. The
amino acid sequences of the 89 peptides are listed individually with the
corresponding index in the TB+ /T B 2 groups in the supplementary
Table S2.
doi:10.1371/journal.pone.0003840.g004
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our study: (i) exclusively recognized in the TB+ group, (ii) exclusively
recognized in the TB2 group and (iii) differentially recognized in
TB+ vs. TB2 individuals (Fig. 3, middlepanel). The 89 differentially
respondingpeptideswerehighlypredictive,withaclassificationerror
of approximately zero. The immune focus on these proteins may, in
part, be biased from the work in the pre-genomic area of MTB
research which targeted proteins secreted into culture medium, or
proteins which have been extensively used in vaccine trials, e.g. the
proteins Esat-6, Ag85B or TB10.4 are more easily available to the
research community since they have been expressed as recombinant
proteins.
Some of the top 100 peptide epitopes identified by antibody
profiling belong to surface-associated MTB proteins (Supplemen-
tary tables S2, S3 and S4 online), other targets belong to factors
associated with subcellular organization, i.e. epitopes from the
RNA polymerase sigma factor F (CAB07069) as well as the Acyl-
CoA Synthase which are recognized in TB+ individuals. These
targets are interesting in the dormant phase of MTB infection for
rational drug design, for example the MTB sigma factor F (sigF) is
responsible for transcriptional initiation [18,19] and Acetyl-CoA
represents the central intermediate in the TCA cycle and in fatty
and amino acid biosynthesis. The use of carbon through Ac-CoA
is critical for survival of non-replicating bacteria, since fatty acids
(and not carbohydrates) present the primary source for carbon in
granulomas. Targeting drugs to this pathway has been suggested
to disrupt the carbon flux necessary for MTB survival [20]. Not a
single individual among the 35 healthy subjects recognized any of
100 epitopes from the sigma factor. In contrast, sigF was
frequently recognized in serum from the 34 individuals with
tuberculosis. Proteins involved in lipid generation and modifica-
tion, such as the cyclopropane fatty-acyl phospholipid synthase
which provides targets for IgG (Fig 3, Supplementary tables S2
and S3 online) and T-cells (defined by IL-2, TNFa and IFNc
production in intracellular cytokine staining, our unpublished
data) may add to the list of immune targets associated with MTB
pathogenesis. Mycolic acids, modified by cyclopropane synthease,
provide major components of the mycobacterial cell wall involved
in MTB persistence. Mycolic acids protect mycobateria against
injuries, decrease permeability for antibiotics and affect MTB
survival within the host phagolysosome [21]. Cyclopropane-
mediated alterations of trehalose dimycolate (cord factor) is
responsible for proinflammatory reactions in early mycobacterial
infection [22].
Most immunology studies are undertaken with the aim of
defining diagnostic markers and identifying new MTB vaccines
[11,23,24]. The cornerstone of studies that investigate the
association between immune-profiling and clinical events is a
well-defined study population. This is very challenging in the
context of TB: although patients with clinical TB were
characterized by pulmonary tests (acid-fast stain positive TB),
the history of the infection could differ from patient to patient. The
positive stain could represent a recently acquired infection or
activation of an infection aquired in the past. Exposure to
environmental bacteria as well as BCG vaccination may also alter
the response to MTB proteins. The same is true for TB2
individuals: in our study, these had not received BCG vaccination,
had tested negative in the tuberculin skin test (TST) and the
Quantiferon test. However, we cannot exclude exposure to
environmental mycobacterial species, e.g. M. fortuitum, M smegmatis.
Figure 5. Ig-recognition: Genetic background and IgA/IgG focus. (A) Genetic background of the test population. Normalized
responses of 5864 peptides detected in all 34 patients with TB+ from Armenia patients and 4733 peptides detected in all 6 TB+ patients from Sweden.
Peptides recognized by one patient group but not the other are assigned the minimum detectable response (approximately 21.0). Peptides that
were not recognized in any of the 35 healthy controls are highlighted in red. (B) Differential epitope recognition in IgA and IgG responses in
patients with TB. Material from 6 individuals with TB, recruited in Stockholm, was tested for IgA and IgG responses directed against the MTB
peptide library. Three groups of peptides are apparent (supplementary Table S6a–c online): those recognized by both IgG and IgA (n=2544 peptide
species, supplementary Table S6a) only by IgG (n=1703 peptides, supplementary Table S6b), or only by IgA (n=845 peptides, supplementary Table
S6c). For peptides not recognized by IgG, we assigned the minimum detectable response (approximately 21.0) on the plot, and similarly for IgA.
Peptides recognized by both IgG and IgA are strongly correlated (r=0.75).
doi:10.1371/journal.pone.0003840.g005
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which may have resulted in a clearance of the infection (the most
likely case in immune-competent individuals) in the absence of a
positive TST and Quantiferon test at the time of the blood draw.
We performed a Blast search of the top 12 peptides exclusively
recognized in TB-negative individuals. If greater variation with the
query peptides was allowed concerning the peptide length,
matches with peptides derived from non-mycobacterial species
were obtained. This would suggest that cross-recognition would
account for anti-peptide specific humoral immune responses in the
TB2 cohort, it could also imply that ‘heterologous immunization’
may contribute for the epitope recognition pattern in TB2
individuals, which is absent in the TB+ cohort. Antigen
recognition signatures in a healthy population will also define
individuals who have been exposed to MTB but who were able to
fight off the infection, worthwhile study subjects for vaccine
developers.
A significant difference between our 2 main groups (TB+ and
TB2 individuals) is not only the geographic location (Armenia and
the US), but also the genetic background. Considering these
caveats, it is surprising that additional serum samples obtained
from individuals testing positive for TB in Sweden shared 60/100
peptide epitopes which were exclusively recognized in 34/34 sera
from the patients with TB from Armenia (supplementary Table S5
online). It is also important to note that none of the peptide
epitopes which are exclusively recognized in the TB-negative
population were recognized by 6/6 serum samples from patients
with TB-infection recruited in Stockholm. In addition, most of the
peptides recognized by any of the patients in a group were
recognized by all. This suggests that TB is most likely associated
with a rather uniform epitope target recognition. In order to
develop the peptide chip described in the current report for
diagnostic purposes, appropriate clinically well defined cohorts
need to be analyzed. For instance, the control sera are from PPD
negative, quantiferon- negative subjects. The use of sera from
absolutely ‘clean controls’ from a non-endemic country and
advanced TB patients has been the major source of problems in
previous efforts to devise a diagnostic assay for TB. The PPD+
subjects from the same geographical area as the patients will
certainly aid to define clinically meaningful biomarkers. However,
the fact that PPD-, ‘clean’, individuals exhibit a uniform
recognition pattern of a defined set of ‘MTB epitopes’, suggests
that ‘cross-recognition’, exposure to MOTT and to other bacterial
or viral species (see supplementary Table S7 online) shapes the
immune recognition profile even in low endemic environments,
and most likely also the immune response to BCG and MTB.
The biological underpinning of differential peptide epitope
recognition could be twofold: first, differential recognition of
MTB-associated proteins may be dependent on antigen accessi-
bility and the nature of presentation. MTB has recently been
shown to access the cytosol of host cells, while BCG or MOTT are
unable to do so [25]. This may in part explain why certain
immune epitopes from the same protein are recognized exclusively in
TB+ and not in TB2 individuals. Second, there is a vast literature
concerning ‘crossreactive’ antibodies that may recognize very
similar epitopes from unrelated targets [26,27] or from closely
related proteins, e.g. TB10.3 and TB12.9 in the case of peptides
derived from TB10.4 [28]. Differential profiling of IgA and IgG,
due to the different half life of the immunoglobulin (IgA has a half
life of 6 days) may aid in dissecting the nature and specificity of the
immune response at the time of the blood draw (Fig. 5B and
Supplementary table S6 online). IgA-mediated immune recogni-
tion of MTB target proteins may also be helpful in designing assays
to gauge anti-MTB recognition profiles in sputum, or to design
MTB vaccines targeting protective immune responses on mucosal
surfaces. In conclusion, high content peptide microarray antibody
profiling represents a powerful tool to visualize the global B-cell
response for diagnostics and vaccine candidates.
Materials and Methods
Patients and slide preparation
Slide production has recently been reported in detail [29]. Slides
with MTB epitopes in the current study were manufactured by
JPT, Germany and consist of two identical subarrays, each with
7776 spots arranged in 24 blocks of 324 spots arranged in columns
and rows of 18. The 7776 peptide spots represent 7446 unique
peptides, 153 negative control spots, 96 Cy3 controls for GAL file
orientation and 24 positive controls spots (4 repetitions each of
IgG, IgA, IgM, IgE). A single slide was prepared using serum from
each of the study subjects; 34 patients who tested positive for active
pulmonary TB (defined by acid fast stain, AFS, in sputum) from
the Medical Yerevan State university hospital in Armenia who
received routine BCG vaccination in childhood, 6 patients with
TB (defined by AFS in sputum and MTB culture) from the
Karolinska Hospital Huddinge and 35 healthy individuals prior to
BCG vaccination (testing negative in the tuberculin skin test (TST)
and the Quantiferon-test) at Saint Louis University, USA. Ethical
approval was obtained from the Stockholm South ethical
committee (Dnr 238/02) for use of the specimens from the
Karolinska Hospital Huddinge, and from St Louis University,
USA (number 12968), for use of the samples provided from
healthy individuals. Ethical approval for the analysis of serum
samples from the Armenian patients is filed at the University of
Mainz, Germany (837.327.99-2271). A further 13 slides (7 from
the batch used for the TB patients, and six from the batch used for
the healthy subjects) were prepared using only buffer and
secondary antibody, in order to help identify peptides giving a
‘false positive’ response, which were removed for further analysis
(see below). Serum obtained from patients with TB or from the
healthy controls was diluted 1:100 using a buffer consisting of PBS,
3% FCS and 0,5% Tween and pipetted onto the slide (300
microliter), on which the incubation area was defined using a
liquid blocker pen before the slide was covered with a cover slip.
Plasma and serum yielded identical results (data not shown). The
slide was incubated at 4uC in a humid chamber for 16 hours. On
day 2, the cover slip was removed and the slide washed five times
(two times rotating in washing solution for 5 minutes, two times
rotating in sterile water for 5 minutes, and finally one rotation in
filtered Milli Q water for 5 minutes). The slide was tapped on dry
tissue to remove droplets and 300 ml of the polyclonal goat anti-
human IgG, heavy and light chain specific, affinity purified Cy5-
labeled secondary reagent (Abcam, cat no: 6561-100, diluted to
1:500) was pipetted at one end of the frame and a cover slip was
carefully applied. Anti-human IgA was a human IgA alpha chain
specific, affinity purified rabbit secondary reagent labeled with
Cy3 (Jackson ImmunoResearch, USA, cat no 309-165-01) and
diluted 1:500. After this step, all work was performed in the dark.
Incubation with the secondary reagent took place for 1 hour at
room temperature in a humid chamber, the 5 washing steps were
repeated, and the slide was dried using a slide centrifuge (Euro
Tech, UK) for 10 seconds.
Scanning and analysis
Each slide was scanned with the GenPix 4000B microarray
scanner (Axon Instruments) at two wavelengths, 532 and 635 nm,
and the images were saved in TIFF and JPG formats.
Peptide Microarray in TB
PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e3840Image analysis was performed utilizing the circular feature
alignment of the GenePix Pro 6.0 software and Genepix Array List
(GAL) files and the following criteria were used to flag spots with
non-uniform foreground or background signal for IgG detection:
([F635 Mean].(1.5*[F635 Median])) AND ([F635 Medi-
an].40)
OR
([B635 Mean].(1.5*[B635 Median])) AND ([B635 Medi-
an].40)
For IgA detection, these same criteria were applied, but with
635 replaced by 532. In addition to these ‘bad’ spots, GenePix also
flagged spots as ‘‘not-found’’ and ‘‘empty’’, resulting in four types
of spots: ‘good’ or ‘non-flagged’ spots (labelled as ‘0’), ‘bad spots’
(labelled as ‘2100’), not-found spots (labelled as ‘250’), and empty
spots (labelled as ‘275’). The digitized image from each sub-array
was saved as a GenePix Result (GPR) file and the median
foreground and background intensities for the 635nm wavelength
from individual peptide spots were used for further analysis of the
IgG responses, and the median foreground and background
intensities of the 532nm wavelength were used for the IgA
responses. All GPR files were saved in a common folder and
imported into R/Bioconductor using the read.GenePix function
from the marray R/Bioconductor package.
Quality data extraction
To examine the quality of the data, we examined the
distribution of the flags. We performed this quality control
exercise for each group, first by combining the data from all the
subarrays and inspecting all spots regardless of whether they were
from control or peptide spots, and subsequently stratifying by the
type of feature. The individual subarray images, produced with the
Image function in Bioconductor, were also visually inspected to
check whether there were any strange or aberrant subarrays that
should not be included in the analysis. The ratio of median
foreground to background (on a log scale) was chosen as the
measure of the strength of the response. The values of this
response index were computed for all spots with background
greater than zero (those with zero background, and thus undefined
index, were noted and excluded). The data for each of the seven
groups of slides (IgG responses from TB+ patients from Armenia,
IgG and IgA from TB+ patients from Sweden, IgG from healthy
subjects, and IgG from three groups of control slides as listed
above) were arranged in a large matrix with identifiers for slide,
subarray, and block, and these master datasets used in all analyses
described below.
Data reduction
The volume of data was reduced while maintaining all the
important information. Removing spots flagged as ‘not found’
would result ina drastic reductionof the data volume, as many spots
have intensity values not substantially different from experimental
noise. However, low responding spots on some slides can be
informative if they represent peptides that have a high response on
one or more of the other slides. Thus, we removed only the ‘‘not-
found’’ spots with high intensity and the spots with no ‘detectable’
response on any slide,where the distributionof the negativecontrols
was used to define a cut-off for a detectable response as follows: for
each slide, we examined first the negative control responses on a
scatterplot of the index vs. the log-background[29] to identify and
eliminate any outliers.The negativecontrolresponsesonall slidesin
a group were then normalized to remove the effects of slide, sub-
array, and block. We performed this normalization using the simple
linear model: Yijk=slidei+subarrj+blockk where Yijk is the response
(i.e. the index) for block k in sub-array j on slide i. The model was
run using the lm function in R, and from the mean and SD of the
normalized values (i.e. the residuals from the regression model) we
defined a threshold for a detectable normalized response as
t=mean+2SD. Every spot with at least one detectable response
on one slide was retained in the analysis.
Identification of false positive peptide responses
Since no peptides are expected to give a detectable response on
a slide with only buffer and secondary antibody, the responding
peptides on the buffer slides were considered as false positives. We
normalized all the valid (i.e. unflagged) peptide responses on these
slides using the same linear model as above applied to each group
in turn. From a scatter plot of the normalized indices vs.
normalised background, the false positives were identified and
excluded in the analysis of the patient data.
Analysis of peptide responses
For each group of patient slides, we used the cut-off from the
negative controls to select all detectable responses for all unflagged
peptides on each slide. If a peptide had no detectable response on
any slide it was excluded from further analysis. All other peptides
had all their responses included i.e. any peptide that had a
detectable response on at least one slide had its responses from all
slides analyzed, whether or not these were above or below the cut-
off. Any peptides defined as false positive by the analysis of the
buffer slides were excluded, and the remaining peptide responses
were normalized using the model Yijk=slidei+subarrj+blockk
where Yijk is the response (i.e. the index) from block k in sub-
array j on slide i. This model was fit using the biglm R-package to
accommodate the much larger dimension of the data. Since
inclusion of a ‘peptide effect’ term in the model was computa-
tionally intractable, we estimated the peptide effects as the
differences between the observed responses and the responses
estimated by the model shown (i.e. the residuals). Since the
systematic effects of slide, subarray, and block have been removed,
we refer to these as the ‘normalized responses’, and we use them as
input data for further analysis (differential expression or predictive
analysis). For the peptides that had replications, their normalized
values were averaged to produce a list of unique peptides with
their normalized values for each slide. The normalized values for
each peptide and slide were stored in one expression matrix for
each group.
Significance and predictive analysis
For each of the groups in the following comparisons, we identified
the peptides that had a normalized response on each slide in the
group, and the peptides that were not common to the two groups: a)
Armenian TB+ vs. controls (IgG), b) Swedish TB+ vs. controls (IgG),
c) Swedish TB IgG vs. Swedish TB IgA. For a) and b), we identified
the common peptides for differential expression analysis, and a two-
group comparison was then carried out using the SAM library in
R[30], and a parallel predictivity analysis was performed using the
PAM library[31]. The proteins from which the peptides are derived
were identified using the GAL file, although peptide sequences could
also be submitted to any online data bank. For all three comparisons
(a,b,c)peptidespresentinonlyone of thegroupswere identifiedand
ranked by the strength of their responses and the number of
replications of the peptide in the group, and these two quantities
illustrated on a plot. For comparison of IgG and IgA responses (IgG
responses using the red channel, and IgA responses using the green
channel) we present the normalized index values in each group on a
scatter plot (Fig 5(b)) to identify strongly recognized IgA and IgG
target epitopes.
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Table S1 Compilation of MTB proteins displayed as linear
peptide stretches on a peptide microarray chip
Found at: doi:10.1371/journal.pone.0003840.s001 (0.09 MB PDF)
Table S2 89 peptides predictive of TB+ (n=34) vs TB2 (n=35)
by PAM analysis
Found at: doi:10.1371/journal.pone.0003840.s002 (0.02 MB PDF)
Table S3 Peptides predictive of TB+ (n=34) vs TB2 (n=35) by
SAM analysis
Found at: doi:10.1371/journal.pone.0003840.s003 (0.08 MB PDF)
Table S4 Top 24 peptides recognized by TB+ patients(n=35)
but not by TB2 controls (n=34) and vice versa
Found at: doi:10.1371/journal.pone.0003840.s004 (0.02 MB PDF)
Table S5 Comparison of MTB peptides defined by IgG in
patients from Armenia and from Sweden.
Found at: doi:10.1371/journal.pone.0003840.s005 (0.19 MB PDF)
Table S6 S6a: MTB Peptides recognized by both IgG and IgA,
S6b: MTB Peptides recognized by IgG and not by IgA, S6c: MTB
Peptides recognized by IgA and not by IgG.
Found at: doi:10.1371/journal.pone.0003840.s006 (0.75 MB PDF)
Table S7 Blast search of the top 12 peptide exclusively
recognized in healthy, PPD-, Quantiferon-negative individuals.
Blast search of the top 12 peptides exclusively recognized in TB-
negative individuals. The peptide amino acid sequence and
peptide number as well as the protein ID and Rv numbers are
provided. The search allowed for at most two amino acids
variation from the query peptide except in some few cases
highlighted with a star (greater variation as compared with the
query peptide). If greater variation with the query peptides was
allowed concerning the peptide length, more matches with
peptides derived from non-mycobacterial species were obtained.
Amino acid differences are marked in red. A detailed blast search
covering all possible permutations of these peptides, followed by
targeted amino acid substitutions and subsequent serum recogni-
tion analysis will aid to define immunogenicity.
Found at: doi:10.1371/journal.pone.0003840.s007 (0.02 MB PDF)
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